Geron Corporation (BIT:1GERN)

Market Cap	917.51M -2.1%
Revenue (ttm)	156.61M +138.8%
Net Income	-71.12M
EPS	-0.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	764
Open	n/a
Previous Close	1.501
Day's Range	n/a
52-Week Range	0.938 - 1.624
Beta	n/a
RSI	56.54
Earnings Date	May 7, 2026

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 258
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1GERN

Financial Performance

In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.

Financial numbers in USD